Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice

Journal of the National Cancer Institute

Volumn 94, Issue 4, 2002, Pages 274-283

  O'Regan, Ruth M ^a   Gajdos, Csaba ^b   Dardes, Rita C ^a   De Los Reyes, Alex ^c   Park, Woochan ^b   Rademaker, Alfred W ^b   Jordan, V Craig ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INCIDENCE; CANCER RECURRENCE; CANCER TRANSPLANTATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EXPOSURE; ENDOMETRIUM TUMOR; FEMALE; GROWTH STIMULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; OVARIECTOMY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TUMOR GROWTH;

EID: 0037138745     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.4.274     Document Type: Article

References (35)

1. Tamoxifen for early breast cancer: An overview of the randomised trials
2. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
3. Phase II evaluation of Ly156758 in metastatic breast cancer
4. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
5. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation
6. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation
7. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats
8. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018
9. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings of the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial
10. Scottish adjuvant tamoxifen trial: A randomized study updated to 15 years
11. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer
12. The prevention and treatment of osteoporosis
13. Cross-resistance of triphenylethylene antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice
14. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer
15. Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro
16. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
17. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse
18. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers
19. Photoaffinity labeling of the progesterone receptor from human endometrial carcinoma
20. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice
21. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration
22. Low dose tamoxifen effectively controls endometrial cancer growth not previously exposed to the drug
23. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182780 on endometrial cancer growth
24. Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogenous breast tumor growth in the athymic mouse
25. Effects of raloxifene after tamoxifen on breast and endometrial cancer growth
26. Effects of high dose raloxifene in selected patients with advanced breast carcinoma
27. Raloxifene hydrochloride
28. Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60
29. Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women
30. Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts
31. The pharmacology and clinical uses of tamoxifen
32. Evidence for the metabolic activation of non-steroidal antioestrogens: A study of structure-activity relationships
33. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials
34. Exemestane is superior to megestrol acetate after tamoxifen failure in post-menopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
35. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate